CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 5, 2010
Result type: Reports
Project Number: SR0197-000
Product Line: Reimbursement Review

Generic Name: Tadalafil

Brand Name: Adcirca

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Pulmonary arterial hypertension

Indications: Pulmonary arterial hypertension

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 15, 2010

Recommendation Type: List with clinical criteria and/or conditions